Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ShorTrip study in locally advanced rectal cancer
2021-001206-29Phase 2Active
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Aug 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan, fluorouracil, folinic acid and oxaliplatin in rectal cancer, sponsored by Gruppo Oncologico Nord Ovest. Primary endpoint: Pathologic complete response rate. Started Aug 2021; status: active.
02
Drugs
irinotecanfluorouracilfolinic acidoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2021-001206-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001206-29.